The European CLARIFY project aims to facilitate the diagnosis of three types of cancer: triple negative breast cancer (TNBC), high-risk non-muscle invasive bladder cancer (HR-NMIBC) and spitzoid melanocytic lesions (SML). In all three cases, their diagnosis is complex and challenging, which CLARIFY aims to address.
To this end, it is working on the development and implementation of advanced artificial intelligence (AI) techniques, image processing and cloud computing applied to the field of digital pathology, also promoting the implementation of a European research network that will integrate European experts in each of these fields and in medicine. This network will enable new synergies between experts in the fields of engineering and medicine; it will contribute to improve the exchange of knowledge and, ultimately, facilitate decision-making in diagnosis and treatment.
In addition, CLARIFY will launch an ambitious multidisciplinary training programme, which will allow twelve young researchers of different nationalities to complete their PhD programmes at one of the institutions participating in the project, learn about the latest scientific advances in AI, cloud computing and digital pathology and enhance new skills, which are key to respond to the challenges of the engineering-medicine binomial for the coming years.
CLARIFY is a partnership between a total of nine organisations from Spain, The Netherlands and Norway.
INCLIVA is in charge of the study of spitzoid melanocytic lesions within the CLARIFY project.
CLARIFY has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No 860627.